Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis

Journal of Autoimmunity

Volumn 63, Issue , 2015, Pages 47-58

  Nezos, Adrianos ^a   Gravani, Fotini ^b   Tassidou, Anna ^c   Kapsogeorgou, Efstathia K ^a   Voulgarelis, Michael ^a   Koutsilieris, Michael ^a   Crow, Mary K ^d   Mavragani, Clio P ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b G GENNIMATAS GENERAL HOSPITAL   (Greece)

^c EVANGELISMOS HOSPITAL   (Greece)

^d HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

B cell activating factor; Lymphomagenesis; Sjogren's syndrome; Type I interferon; Type II interferon

Indexed keywords

ALPHA INTERFERON; B CELL ACTIVATING FACTOR; GAMMA INTERFERON; LA ANTIBODY; MESSENGER RNA; RHEUMATOID FACTOR; RO ANTIBODY; BIOLOGICAL MARKER; INTERFERON;

ADOLESCENT; ADULT; ARTHRALGIA; ARTHRITIS; ARTICLE; CARCINOGENESIS; CHOLANGITIS; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CRYOGLOBULINEMIA; DISEASE DURATION; DRY EYE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENE; GENE OVEREXPRESSION; GLOMERULONEPHRITIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERGAMMAGLOBULINEMIA; HYPOCOMPLEMENTEMIA; INTERFERON INDUCIBLE GENE; INTERSTITIAL NEPHRITIS; LEUKOPENIA; LIVER DISEASE; LUNG DISEASE; LYMPHADENOPATHY; LYMPHOCYTOPENIA; LYMPHOMA; LYMPHOMAGENESIS; MALE; MINOR SALIVA GLAND; PERIPHERAL NEUROPATHY; PHENOTYPE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PURPURA; RAYNAUD PHENOMENON; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; SALIVARY GLAND BIOPSY; SALIVARY GLAND DISEASE; SEROLOGY; SJOEGREN SYNDROME; XEROSTOMIA; BLOOD; METABOLISM; MIDDLE AGED; SJOGREN'S SYNDROME;

ADULT; BIOMARKERS; FEMALE; HUMANS; INTERFERON TYPE I; INTERFERON-GAMMA; LYMPHOMA; MALE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; SALIVARY GLANDS, MINOR; SJOGREN'S SYNDROME;

EID: 84940836792     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2015.07.002     Document Type: Article

References (57)

1. Mavragani C.P., Moutsopoulos H.M. Sjogren's syndrome. Annu. Rev. Pathol. 2014, 9:273-285.
2. Zintzaras E., Voulgarelis M., Moutsopoulos H.M. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch. Intern. Med. 2005, 165:2337-2344.
3. Ioannidis J.P., Vassiliou V.A., Moutsopoulos H.M. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthritis Rheum. 2002, 46:741-747.
4. Manoussakis M.N., Boiu S., Korkolopoulou P., Kapsogeorgou E.K., Kavantzas N., Ziakas P., et al. Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjogren's syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development. Arthritis Rheum. 2007, 56:3977-3988.
5. Theander E., Vasaitis L., Baecklund E., Nordmark G., Warfvinge G., Liedholm R., et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndrome. Ann. Rheum. Dis. 2011, 70:1363-1368.
6. Tapinos N.I., Polihronis M., Moutsopoulos H.M. Lymphoma development in Sjogren's syndrome: novel p53 mutations. Arthritis Rheum. 1999, 42:1466-1472.
7. Pisa E.K., Pisa P., Kang H.I., Fox R.I. High frequency of t(14;18) translocation in salivary gland lymphomas from Sjogren's syndrome patients. J. Exp. Med. 1991, 174:1245-1250.
8. Nezos A., Papageorgiou A., Fragoulis G., Ioakeimidis D., Koutsilieris M., Tzioufas A.G., et al. B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome. J. Autoimmun. 2014, 51:89-98.
9. Nocturne G., Boudaoud S., Miceli-Richard C., Viengchareun S., Lazure T., Nititham J., et al. Germline and somatic genetic variations of TNFAIP3 in lymphoma complicating primary Sjogren's syndrome. Blood 2013, 122:4068-4076.
10. Papageorgiou A., Mavragani C.P., Nezos A., Zintzaras E., Quartuccio L., De Vita S., et al. A B-cell activating factor receptor (BAFF-R) His159Tyr mutation in Sjogren's Syndrome related lymphoproliferation. Arthritis Rheumatol 2015, (Hoboken, NJ).
11. Gottenberg J.E., Cagnard N., Lucchesi C., Letourneur F., Mistou S., Lazure T., et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:2770-2775.
12. Vakaloglou K.M., Mavragani C.P. Activation of the type I interferon pathway in primary Sjogren's syndrome: an update. Curr. Opin. Rheumatol. 2011, 23:459-464.
13. Brkic Z., Maria N.I., van Helden-Meeuwsen C.G., van de Merwe J.P., van Daele P.L., Dalm V.A., et al. Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expression. Ann. Rheum. Dis. 2013, 72:728-735.
14. Mavragani C.P., Crow M.K. Activation of the type I interferon pathway in primary Sjogren's syndrome. J. Autoimmun. 2010, 35:225-231.
15. Hjelmervik T.O., Petersen K., Jonassen I., Jonsson R., Bolstad A.I. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. Arthritis Rheum. 2005, 52:1534-1544.
16. Emamian E.S., Leon J.M., Lessard C.J., Grandits M., Baechler E.C., Gaffney P.M., et al. Peripheral blood gene expression profiling in Sjogren's syndrome. Genes Immun. 2009, 10:285-296.
17. Mavragani C.P., Niewold T.B., Moutsopoulos N.M., Pillemer S.R., Wahl S.M., Crow M.K. Augmented interferon-alpha pathway activation in patients with Sjogren's syndrome treated with etanercept. Arthritis Rheum. 2007, 56:3995-4004.
18. Wildenberg M.E., van Helden-Meeuwsen C.G., van de Merwe J.P., Drexhage H.A., Versnel M.A. Systemic increase in type I interferon activity in Sjogren's syndrome: a putative role for plasmacytoid dendritic cells. Eur. J. Immunol. 2008, 38:2024-2033.
19. Hall J.C., Casciola-Rosen L., Berger A.E., Kapsogeorgou E.K., Cheadle C., Tzioufas A.G., et al. Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:17609-17614.
20. Hertzog P., Forster S., Samarajiwa S. Systems biology of interferon responses. J. Interferon Cytokine Res. Official J. Int. Soc. Interferon Cytokine Res. 2011, 31:5-11.
21. Ogawa N., Ping L., Zhenjun L., Takada Y., Sugai S. Involvement of the interferon-gamma-induced T cell-attracting chemokines, interferon-gamma-inducible 10-kd protein (CXCL10) and monokine induced by interferon-gamma (CXCL9), in the salivary gland lesions of patients with Sjogren's syndrome. Arthritis Rheum. 2002, 46:2730-2741.
22. Ronnblom L., Eloranta M.L. The interferon signature in autoimmune diseases. Curr. Opin. Rheumatol. 2013, 25:248-253.
23. Cha S., Brayer J., Gao J., Brown V., Killedar S., Yasunari U., et al. A dual role for interferon-gamma in the pathogenesis of Sjogren's syndrome-like autoimmune exocrinopathy in the nonobese diabetic mouse. Scand. J. Immunol. 2004, 60:552-565.
24. Nguyen C.Q., Peck A.B. The interferon-signature of Sjogren's syndrome: how unique biomarkers can identify underlying inflammatory and immunopathological mechanisms of specific diseases. Front. Immunol. 2013, 4:142.
25. Pollard K.M., Cauvi D.M., Toomey C.B., Morris K.V., Kono D.H. Interferon-gamma and systemic autoimmunity. Discov. Med. 2013, 16:123-131.
26. Billiau A., Matthys P. Interferon-gamma: a historical perspective. Cytokine Growth Factor Rev. 2009, 20:97-113.
27. Hu X., Ivashkiv L.B. Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. Immunity 2009, 31:539-550.
28. Hall J.C., Baer A.N., Shah A.A., Criswell L.A., Shiboski C.H., Rosen A., et al. Molecular subsetting of interferon pathways in Sjogren's syndrome. Arthritis Rheumatol. 2015, (Hoboken, NJ).
29. Mavragani C.P., Moutsopoulos H.M. Sjogren syndrome. CMAJ 2014, 186:E579-E586.
30. Wakamatsu E., Nakamura Y., Matsumoto I., Goto D., Ito S., Tsutsumi A., et al. DNA microarray analysis of labial salivary glands of patients with Sjogren's syndrome. Ann. Rheum. Dis. 2007, 66:844-845.
31. Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H.M., Alexander E.L., Carsons S.E., et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann. Rheum. Dis. 2002, 61:554-558.
32. Hua J., Kirou K., Lee C., Crow M.K. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum. 2006, 54:1906-1916.
33. Kirou K.A., Lee C., George S., Louca K., Papagiannis I.G., Peterson M.G., et al. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum. 2004, 50:3958-3967.
34. Maria N.I., Brkic Z., Waris M., van Helden-Meeuwsen C.G., Heezen K., van de Merwe J.P., et al. MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren's syndrome. Ann. Rheum. Dis. 2013, 73:1052-1059.
35. Kumar-Sinha C., Varambally S., Sreekumar A., Chinnaiyan A.M. Molecular cross-talk between the TRAIL and interferon signaling pathways. J. Biol. Chem. 2002, 277:575-585.
36. Porta C., Hadj-Slimane R., Nejmeddine M., Pampin M., Tovey M.G., Espert L., et al. Interferons alpha and gamma induce p53-dependent and p53-independent apoptosis, respectively. Oncogene 2005, 24:605-615.
37. Strandberg L., Ambrosi A., Espinosa A., Ottosson L., Eloranta M.L., Zhou W., et al. Interferon-alpha induces up-regulation and nuclear translocation of the Ro52 autoantigen as detected by a panel of novel Ro52-specific monoclonal antibodies. J. Clin. Immunol. 2008, 28:220-231.
38. Jauharoh S.N., Saegusa J., Sugimoto T., Ardianto B., Kasagi S., Sugiyama D., et al. SS-A/Ro52 promotes apoptosis by regulating Bcl-2 production. Biochem. Biophys. Res. Commun. 2012, 417:582-587.
39. Mariette X., Roux S., Zhang J., Bengoufa D., Lavie F., Zhou T., et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann. Rheum. Dis. 2003, 62:168-171.
40. Ittah M., Miceli-Richard C., Eric Gottenberg J., Lavie F., Lazure T., Ba N., et al. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren's syndrome. Arthritis Res. Ther. 2006, 8:R51.
41. Lavie F., Miceli-Richard C., Ittah M., Sellam J., Gottenberg J.E., Mariette X. B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjogren's syndrome. Scand. J. Immunol. 2008, 67:185-192.
42. Kirou K.A., Mavragani C.P., Crow M.K. Activation of type I interferon in systemic lupus erythematosus. Expert Rev. Clin. Immunol. 2007, 3:579-588.
43. Mavragani C.P., Niewold T.B., Chatzigeorgiou A., Danielides S., Thomas D., Kirou K.A., et al. Increased serum type I interferon activity in organ-specific autoimmune disorders: clinical, imaging, and serological associations. Front. Immunol. 2013, 4:238.
44. Dastmalchi M., Grundtman C., Alexanderson H., Mavragani C.P., Einarsdottir H., Helmers S.B., et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann. Rheum. Dis. 2008, 67:1670-1677.
45. Markowitz J., Luedke E.A., Grignol V.P., Hade E.M., Paul B.K., Mundy-Bosse B.L., et al. A phase I trial of bortezomib and interferon-alpha-2b in metastatic melanoma. J. Immunother. 2014, 37:55-62.
46. Thyrell L., Erickson S., Zhivotovsky B., Pokrovskaja K., Sangfelt O., Castro J., et al. Mechanisms of Interferon-alpha induced apoptosis in malignant cells. Oncogene 2002, 21:1251-1262.
47. Kirou K.A., Vakkalanka R.K., Butler M.J., Crow M.K. Induction of Fas ligand-mediated apoptosis by interferon-alpha. Clin. Immunol. 2000, 95:218-226.
48. Sacre K., Criswell L.A., McCune J.M. Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res. Ther. 2012, 14:R155.
49. Manoussakis M.N., Moutsopoulos H.M. Antimalarials in Sjogren's syndrome-the Greek experience. Lupus 1996, 5(Suppl. 1):S28-S30.
50. Carubbi F., Alunno A., Cipriani P., Bartoloni E., Baldini C., Quartuccio L., et al. A retrospective, multicenter study evaluating the prognostic value of minor salivary gland histology in a large cohort of patients with primary Sjogren's syndrome. Lupus 2015, 24:315-320.
51. Willeke P., Schluter B., Schotte H., Domschke W., Gaubitz M., Becker H. Interferon-gamma is increased in patients with primary Sjogren's syndrome and Raynaud's phenomenon. Semin. Arthritis Rheum. 2009, 39:197-202.
52. Mitsias D.I., Tzioufas A.G., Veiopoulou C., Zintzaras E., Tassios I.K., Kogopoulou O., et al. The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren's syndrome. Clin. Exp. Immunol. 2002, 128:562-568.
53. Riedel S., Kraft M., Kucharzik T., Pauels H.G., Tiemann M., Steinbuchel A., et al. CD4+ Th1-cells predominate in low-grade B-cell lymphoma of gastric mucosa-associated lymphoid tissue (MALT type). Scand. J. Gastroenterol. 2001, 36:1198-1203.
54. Hauer A.C., Finn T.M., MacDonald T.T., Spencer J., Isaacson P.G. Analysis of TH1 and TH2 cytokine production in low grade B cell gastric MALT-type lymphomas stimulated in vitro with Helicobacter pylori. J. Clin. Pathol. 1997, 50:957-959.
55. Rusakiewicz S., Nocturne G., Lazure T., Semeraro M., Flament C., Caillat-Zucman S., et al. NCR3/NKp30 contributes to pathogenesis in primary Sjogren's syndrome. Sci. Transl. Med. 2013, 5:195ra96.
56. Yang L., Yamamoto K., Nishiumi S., Nakamura M., Matsui H., Takahashi S., et al. Interferon-gamma-producing B cells induce the formation of gastric lymphoid follicles after Helicobacter suis infection. Mucosal Immunol. 2014, 8:279-295.
57. Kubo-Murai M., Hazeki K., Nigorikawa K., Omoto T., Inoue N., Hazeki O. IRAK-4-dependent degradation of IRAK-1 is a negative feedback signal for TLR-mediated NF-kappaB activation. J. Biochem. 2008, 143:295-302.